Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder

Eric Hollander, Bernardo Dell'Osso

Research output: Contribution to journalArticlepeer-review


We report a case of treatment-resistant obsessive-compulsive disorder (OCD) that was successfully treated with a pharmacological augmentation of topiramate plus paroxetine. The patient, a 45-year-old woman, was on a stable dose of paroxetine (40 mg/day) when she was started on topiramate (up to 150 mg/day). After 9 weeks of this treatment, her clinical condition remarkably improved, as indicated by a significant decrease of the evaluation scales (Yale-Brown Obsessive-Compulsive Scale and Clinical Global Impression Scale). Our case suggests that topiramate might be beneficial in augmentation with selective serotonin reuptake inhibitors in patients with treatment-resistant OCD, although further investigations are warranted to confirm our findings.

Original languageEnglish
Pages (from-to)189-191
Number of pages3
JournalInternational Clinical Psychopharmacology
Issue number3
Publication statusPublished - May 2006


  • Augmentation
  • Obsessive-compulsive disorder
  • Paroxetine
  • Topiramate
  • Treatment-resistant

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder'. Together they form a unique fingerprint.

Cite this